P

Inventor

BELL NOAH

US20 patents
⚠️ This page may combine multiple inventors who share the name “BELL NOAH”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

ARDELYX INC

19 patents
US9408840B2Aug 9, 2016

Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorder

ARDELYX INC6 citations83
US8916569B2Dec 23, 2014

Compounds and methods for inhibiting phosphate transport

ARDELYX INC7 citations83
US8815910B2Aug 26, 2014

Compounds and methods for inhibiting phosphate transport

ARDELYX INC7 citations83
US8815908B2Aug 26, 2014

Compounds and methods for inhibiting phosphate transport

ARDELYX INC7 citations83
US8809339B2Aug 19, 2014

Compounds and methods for inhibiting phosphate transport

ARDELYX INC8 citations83
US11318129B2May 3, 2022

Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders

ARDELYX INC1 citations72
US10543207B2Jan 28, 2020

Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders

ARDELYX INC3 citations72
US10385024B2Aug 20, 2019

Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders

ARDELYX INC3 citations72
US10968246B2Apr 6, 2021

Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists

ARDELYX INC2 citations71
US10392413B2Aug 27, 2019

Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists

ARDELYX INC3 citations71
US10376481B2Aug 13, 2019

Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders

ARDELYX INC3 citations71
US9006281B2Apr 14, 2015

Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders

ARDELYX INC1 citations62
US8969377B2Mar 3, 2015

Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders

ARDELYX INC3 citations62
US12016856B2Jun 25, 2024

Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders

ARDELYX INC0 citations61
US9301951B2Apr 5, 2016

Compounds and methods for inhibiting phosphate transport

ARDELYX INC0 citations51
US9289430B2Mar 22, 2016

Compounds and methods for inhibiting phosphate transport

ARDELYX INC0 citations51
US9289429B2Mar 22, 2016

Compounds and methods for inhibiting phosphate transport

ARDELYX INC0 citations51
US9278102B2Mar 8, 2016

Compounds and methods for inhibiting phosphate transport

ARDELYX INC0 citations51
US12084472B2Sep 10, 2024

Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists

ARDELYX INC0 citations50

CHARMOT DOMINIQUE

1 patent